Comparison of GLP-1 drugs, SGLT2 inhibitors, and finerenone for cardiovascular and renal benefits in diabetes evaluates which drug class provides optimal organ protection.
Key findingComparison of GLP-1 drugs, SGLT2 inhibitors, and finerenone for cardiovascular and renal benefits in
What the researchers found
Comparison of GLP-1 drugs, SGLT2 inhibitors, and finerenone for cardiovascular and renal benefits in diabetes evaluates which drug class provides optimal organ protection.
Why it matters
Relevant to peptide therapeutics.
The numbers in context
Network meta-analysis through December 2024 comparing three drug classes across cardiovascular and renal endpoints in T2D.
How the study worked
In publication.
Who was studied
Type 2 diabetes patients in cardiovascular and renal outcome RCTs across three drug classes
What this study cannot tell us
In publication.
How to read the evidence
Based on design.
When this study was published
Published in 2025.
The bigger picture
Advances peptide evidence.
Questions still open
- Long-term implications?
- Evidence comparison?
- Next steps?
Common questions
What does this mean?
How reliable?
Read the original research
Comparison of three types of drugs for cardiovascular and renal benefits in type 2 diabetes mellitus.
World journal of diabetes, 16(11), 111280
Citation
An, Xue-Dong; Li, Xin-Qin; Zhang, He; Jia, Qian-You; Zhang, Yue-Hong; Yang, Gui-Gui. (2025). Comparison of three types of drugs for cardiovascular and renal benefits in type 2 diabetes mellitus.. World journal of diabetes, 16(11), 111280. https://doi.org/10.4239/wjd.v16.i11.111280